Abstract
Due to the advancements in modern medicine that have resulted in an increased number of immunocompromised individuals, the incidences and the associated mortality of invasive aspergillosis have continued to rise over the past three decades despite appropriate treatment. As a result, invasive aspergillosis has emerged as a leading cause of infection-related mortality in immunocompromised individuals. Utilizing the resazurin to resorufin conversion fluorescence readout to monitor cell viability, herein, we outline a high-throughput screening method amenable to profiling a large pharmaceutical library against the clinically relevant but less frequently screened fungal pathogen Aspergillus fumigatus. This enables the user to conduct high-throughput screening using a disease-relevant fungal growth assay and identify novel antifungal chemotypes as drug leads.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lin S, Schranz J, Teutsch S (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32(3):358–366
McNeil M, Nash S, Hajjeh R, Phelan M, Conn L, Plikaytis B, Warnock D (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 33(5):641–647
Zmeili O, Soubani A (2007) Pulmonary aspergillosis: a clinical update. QJM 100(6):317–334
Morgan J, Wannemuehler K, Marr K, Hadley S, Kontoyiannis D, Walsh T, Fridkin S, Pappas P, Warnock D (2005) Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43(1):S49–S58
Wilson L, Reyes C, Stolpman M, Speckman J, Allen K, Beney J (2002) The direct cost and incidence of systemic fungal infections. Value Health 5(1):26–34
Hospenthal D, Kwon-Chung K, Bennett J (1998) Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 36(3):165–168
Goodley J, Clayton Y, Hay R (1994) Environmental sampling for aspergilli during building construction on a hospital site. J Hosp Infect 26(1):27–35
Brakhage J (2006) Molecular determinates of virulence in Aspegillus fumigatus. In: Heitman J (ed) Molecular principles of fungal pathogenesis. ASM Press, Washington, DC
Latgé J (1999) Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12(2):310–350
Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J, Kern W, Marr K, Ribaud P, Lortholary O, Sylvester R, Rubin R, Wingard J, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar P, Hodges M, Schlamm H, Troke P, Bd P (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408–415
Rampersad S (2012) Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors 12(9):12347–12360
Pesch K, Simmert U (1929) Combined assays for lactose and galactose by enzymatic reactions. Milchw Forsch 8:551
Stoddart M (2011) Cell viability assays: introduction. Methods Mol Biol 740:1–6
O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267(17):5421–5426
Ahmed S, Jr RG, Walsh J (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170(2):211–224
Fai P, Grant A (2009) A rapid resazurin bioassay for assessing the toxicity of fungicides. Chemosphere 74(9):1165–1170
Monteiro M, Mdl C, Cantizani J, Moreno C, Tormo J, Mellado E, Lucas JD, Asensio F, Valiante V, Brakhage A, Latgé J, Genilloud O, Vicente F (2012) A new approach to drug discovery: high-throughput screening of microbial natural extracts against Aspergillus fumigatus using resazurin. J Biomol Screen 17(4):542–549
Mania D, Hilpert K, Ruden S, Fischer R, Takeshita N (2010) Screening for antifungal peptides and their modes of action in Aspergillus nidulans. Appl Environ Microbiol 76(21):7102–7108
Yamaguchi H, Uchida K, Nagino K, Matsunaga T (2002) Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole. J Infect Chemother 8(4):374–377
Araujo R, Rodrigues A (2004) Variability of germinative potential among pathogenic species of Aspergillus. J Clin Microbiol 42(9):4335–4337
Acknowledgements
We would like to thank the Aspergillus fumigatus inhibitor project team including Neil Ryder, Kathryn Thompson, Roger Fujimoto, Joseph Drumm, and Dominic Hoepfner for scientific input and advice during the screen. We would like to thank Heidi Faw for safety considerations regarding Aspergillus handling. We would like to thank Alejandra Raimondi for initial assay development work. We would like to thank Melissa Grippo for compound purity testing by LC-MS.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Smith, T.M., Richie, D.L., Tao, J. (2016). A Fluorescence-Based High-Throughput Screening Assay to Identify Growth Inhibitors of the Pathogenic Fungus Aspergillus fumigatus . In: Janzen, W. (eds) High Throughput Screening. Methods in Molecular Biology, vol 1439. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3673-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3673-1_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3671-7
Online ISBN: 978-1-4939-3673-1
eBook Packages: Springer Protocols